2025 United States Autologous Cell Therapy Market Revenue Opportunities Report
Description
The 2025 United States Autologous Cell Therapy Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Autologous Cell Therapy Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the U.S. autologous cell therapy market are Bristol Myers Squibb (BMS), Gilead Sciences (Kite Pharma), Novartis, and Caladrius Biosciences Inc. These firms lead through extensive clinical trials, FDA approvals, and innovative cell therapy developments. Bristol Myers Squibb, with its acquisition of Celgene, markets therapies like ABECMA and CARVYKTI. Gilead's Kite Pharma is noted for its CAR-T therapies including Yescarta with enhanced manufacturing processes approved by the FDA. Novartis maintains a robust pipeline and global presence, contributing significantly to market growth. Caladrius Biosciences is also a U.S.-based player focusing on regenerative autologous therapies for rare diseases and cardiovascular conditions.
North America dominates the market with a revenue share around 57%-60% due to the U.S.'s advanced healthcare infrastructure, high R&D investment, and regulatory support. The rising burden of chronic diseases like cancer and autoimmune disorders fuels demand. Partnerships and mergers, such as Selecta Biosciences with Cartesian Therapeutics, advance RNA and cell therapy innovation. The market is projected to reach a valuation of approximately USD 17 billion in the U.S. by 2034, driven by ongoing clinical developments and strong intellectual property protections.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Autologous Cell Therapy Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the U.S. autologous cell therapy market are Bristol Myers Squibb (BMS), Gilead Sciences (Kite Pharma), Novartis, and Caladrius Biosciences Inc. These firms lead through extensive clinical trials, FDA approvals, and innovative cell therapy developments. Bristol Myers Squibb, with its acquisition of Celgene, markets therapies like ABECMA and CARVYKTI. Gilead's Kite Pharma is noted for its CAR-T therapies including Yescarta with enhanced manufacturing processes approved by the FDA. Novartis maintains a robust pipeline and global presence, contributing significantly to market growth. Caladrius Biosciences is also a U.S.-based player focusing on regenerative autologous therapies for rare diseases and cardiovascular conditions.
North America dominates the market with a revenue share around 57%-60% due to the U.S.'s advanced healthcare infrastructure, high R&D investment, and regulatory support. The rising burden of chronic diseases like cancer and autoimmune disorders fuels demand. Partnerships and mergers, such as Selecta Biosciences with Cartesian Therapeutics, advance RNA and cell therapy innovation. The market is projected to reach a valuation of approximately USD 17 billion in the U.S. by 2034, driven by ongoing clinical developments and strong intellectual property protections.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
